Fibroblast Growth Factor Receptor Inhibitor–Associated Multifocal Serous Retinal Detachments: A Case Report. (July 2022)

• Record Type: Journal Article
• Authors: Kim, Diana H.; Xia, Tian; Bracha, Peter; VanderBeek, Brian L.
• Is Part Of: Journal of vitreoretinal diseases. Volume 6:Number 4(2022)
• Page Start: 337
• Page End: 340
• Publication Date: 2022-07
• Subjects: drug reactions -- erdafitinib -- fibroblast growth factor receptor inhibitor -- serous retinal detachments -- urothelial carcinoma; Retina -- Diseases -- Periodicals; Vitreous body -- Diseases -- Periodicals; Retina -- Diseases; Vitreous body -- Diseases; Periodicals; 617.735005
• DOI: 10.1177/24741264211013629
• Languages: English
• ISSNs: 2474-1264

Abstract

Purpose: This report aims to describe a case of bilateral, multifocal neurosensory retinal detachments that developed during erdafitinib therapy for metastatic urothelial carcinoma. Methods: A case report with color fundus imaging and spectral-domain optical coherence tomography imaging is presented. Results: A 50-year-old man with metastatic urothelial carcinoma had an unremarkable baseline ophthalmic examination prior to starting erdafitinib. At 3-month follow up, an examination revealed bilateral, multifocal retinal detachments. Because the patient was asymptomatic and erdafitinib was the only drug to which his tumor had responded, he was kept on the medication with close ophthalmic monitoring. Conclusions: Erdafitinib, a fibroblast growth factor receptor inhibitor, can cause bilateral, multifocal retinal detachments. Continuation of erdafitinib may be considered in patients without significant visual impairment when the overall benefit of the medication appears to outweigh the risks.